Forrest W A
J Int Med Res. 1981;9(6):490-4. doi: 10.1177/030006058100900611.
Six hundred and forty-eight previously treated hypertensive patients, with a mean age of 64 years, were studied. In spite of treatment over a mean period of 18 months, their blood pressure was inadequately controlled, with an initial mean level of 180/108 mm Hg. Previous treatment which had consisted of either a diuretic alone, a beta-receptor antagonist alone or these two drugs in combination was discontinued and patients were randomly allocated, in double-blind manner, to a 6-week treatment course of cyclopenthiazide (Navidrex) or sustained release oxprenolol (Slow-Trasicor) or a fixed combination of these two compounds (Trasidrex) with the aim of lowering the diastolic pressure to less than 100 mm Hg. Blood pressure was substantially reduced in each treatment group, with the lowest final pressures in the group treated with the fixed combination, where 87% of the patients completing the study reached the target level of a diastolic pressure of less than 100 mm Hg. Very few side-effects of treatment were reported with any of these compounds. The results from this study suggest that these compounds in their standard dosage range are useful and safe antihypertensive agents in older patients. In those patients where blood pressure control with a single agent was proving difficult, the transfer to one or two tablets daily of the fixed combination (Trasidrex) produced a very satisfactory outcome in the large majority of cases.
对648名既往接受过治疗的高血压患者进行了研究,这些患者的平均年龄为64岁。尽管平均治疗时间为18个月,但他们的血压控制不佳,初始平均水平为180/108 mmHg。既往治疗包括单独使用利尿剂、单独使用β受体拮抗剂或这两种药物联合使用,现停止这些治疗,患者以双盲方式随机分配,接受为期6周的环戊噻嗪(萘呋胺酯)或氧烯洛尔缓释剂(慢心利)或这两种化合物的固定组合(复方降压片)治疗,目的是将舒张压降至100 mmHg以下。每个治疗组的血压均显著降低,固定组合治疗组的最终血压最低,完成研究的患者中有87%达到了舒张压低于100 mmHg的目标水平。使用这些化合物治疗报告的副作用很少。这项研究的结果表明,这些化合物在其标准剂量范围内是老年患者有用且安全的抗高血压药物。在那些单用一种药物难以控制血压的患者中,大多数情况下,换用每日1或2片的固定组合(复方降压片)可产生非常满意的效果。